Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Mipomersen (kynamro): a novel antisense oligonucleotide inhibitor for the management of homozygous familial hypercholesterolemia.

Literature DB >> 24669178

Mipomersen (kynamro): a novel antisense oligonucleotide inhibitor for the management of homozygous familial hypercholesterolemia.

Elaine Wong, Tamara Goldberg.

Abstract

Mipomersen (Kynamro) for homozygous familial hypercholesterolemia.

Entities: Chemical Disease

Year: 2014 PMID： 24669178 PMCID： PMC3956393

Source DB: PubMed Journal: P T ISSN： 1052-1372

16 in total

1. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

Authors:
Journal: Circulation Date: 2002-12-17 Impact factor: 29.690

Review 2. Antisense oligonucleotides: basic concepts and mechanisms.

Authors: Nathalie Dias; C A Stein
Journal: Mol Cancer Ther Date: 2002-03 Impact factor: 6.261

3. Novel therapies and new targets of treatment for familial hypercholesterolemia.

Authors: Anne Carol Goldberg
Journal: J Clin Lipidol Date: 2010-08-21 Impact factor: 4.766

Review 4. Development of apolipoprotein B antisense molecules as a therapy for hyperlipidemia.

Authors: Tiffany Thomas; Henry Ginsberg
Journal: Curr Atheroscler Rep Date: 2010-01 Impact factor: 5.113

5. Management of familial hypercholesterolemias in adult patients: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia.

Authors: Matthew K Ito; Mary P McGowan; Patrick M Moriarty
Journal: J Clin Lipidol Date: 2011-04-08 Impact factor: 4.766

Review 6. Mipomersen: a safe and effective antisense therapy adjunct to statins in patients with hypercholesterolemia.

Authors: Daniel N Ricotta; William Frishman
Journal: Cardiol Rev Date: 2012 Mar-Apr Impact factor: 2.644

Review 7. Cell and molecular biology of the assembly and secretion of apolipoprotein B-containing lipoproteins by the liver.

Authors: R A Davis
Journal: Biochim Biophys Acta Date: 1999-08-25

8. Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia.

Authors: Fatima Akdim; Diane L Tribble; JoAnn D Flaim; Rosie Yu; John Su; Richard S Geary; Brenda F Baker; Rainard Fuhr; Mark K Wedel; John J P Kastelein
Journal: Eur Heart J Date: 2011-05-18 Impact factor: 29.983

9. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease.

Authors: Evan A Stein; Robert Dufour; Claude Gagne; Daniel Gaudet; Cara East; Joanne M Donovan; Wai Chin; Diane L Tribble; Mary McGowan
Journal: Circulation Date: 2012-10-11 Impact factor: 29.690

Review 10. Management of familial hypercholesterolemia: a review of the recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia.

Authors: Jennifer G Robinson
Journal: J Manag Care Pharm Date: 2013-03

27 in total

Review 1. The role of antisense oligonucleotide therapy in patients with familial hypercholesterolemia: risks, benefits, and management recommendations.

Authors: Anandita Agarwala; Peter Jones; Vijay Nambi
Journal: Curr Atheroscler Rep Date: 2015-01 Impact factor: 5.113

Mipomersen (kynamro): a novel antisense oligonucleotide inhibitor for the management of homozygous familial hypercholesterolemia.

1. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

Review 2. Antisense oligonucleotides: basic concepts and mechanisms.

3. Novel therapies and new targets of treatment for familial hypercholesterolemia.

Review 4. Development of apolipoprotein B antisense molecules as a therapy for hyperlipidemia.

5. Management of familial hypercholesterolemias in adult patients: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia.

Review 6. Mipomersen: a safe and effective antisense therapy adjunct to statins in patients with hypercholesterolemia.

Review 7. Cell and molecular biology of the assembly and secretion of apolipoprotein B-containing lipoproteins by the liver.

8. Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia.

9. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease.

Review 10. Management of familial hypercholesterolemia: a review of the recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia.

Review 1. The role of antisense oligonucleotide therapy in patients with familial hypercholesterolemia: risks, benefits, and management recommendations.

Review 2. Can modulators of apolipoproteinB biogenesis serve as an alternate target for cholesterol-lowering drugs?

Review 3. Therapeutic nucleic acids: current clinical status.

Review 4. Induced protein degradation: an emerging drug discovery paradigm.

Review 5. Current Treatment of Dyslipidemia: Evolving Roles of Non-Statin and Newer Drugs.

Review 6. Apolipoproteins in vascular biology and atherosclerotic disease.

Review 7. Tendon Pathology in Hypercholesterolemia and Familial Hypercholesterolemia.

Review 8. Pharmacokinetics and Proceedings in Clinical Application of Nucleic Acid Therapeutics.

Review 9. Translating genetic association of lipid levels for biological and clinical application.

Review 10. In vivo and in vitro studies of antisense oligonucleotides - a review.